Navigation Links
Cervical in Medical Technology

Society of Gynecologic Oncologists Issues White Paper on HPV Vaccine's Impact on Cervical Cancer Prevention

Paper is First in a Series Based on Presentations from Cervical Cancer Prevention Forum Hosted by SGO CHICAGO, Aug. 3 /PRNewswire-USNewswire/ -- The Society of Gynecologic Oncologists (SGO) has published the first in a series of four papers on a variety of cervical cancer i...

Landmark Study for GSK's Cervical Cancer Vaccine Published in The Lancet

LONDON, July 7 /PRNewswire/ -- The final analysis of the largest efficacy trial of a cervical cancer vaccine is published today in The Lancet . The study, involving 18,644 women, confirmed GlaxoSmithKline's Cervarix (R) is highly effective at protecting against the two most common cervical cance...

Study Showed Lilly's GEMZAR(R) (gemcitabine HCl for injection) Improved Progression-Free Survival in Cervical Cancer Patients

ORLANDO, Fla., May 31 /PRNewswire-FirstCall/ -- Eli Lilly and Company announced today that Phase III trial data showed the addition of Lilly's GEMZAR(R) (gemcitabine HCl for injection) to the current standard of care provided a statistically significant increase in progression-free survival at thr...

Des Moines Register Reports SpectraScience LUMA Enhances Cervical Cancer Exams

SAN DIEGO, April 30 /PRNewswire-FirstCall/ -- SpectraScience, Inc. (OTC Bulletin Board: SCIE) , a San Diego based medical device company, announced today that Iowa's Des Moines Register published an article reporting that its LUMA cervical imaging system is enhancing the effectiveness of cancer ...

Landmark Study in The New England Journal of Medicine Shows HPV Testing Significantly Reduces Deaths from Cervical Cancer, Compared to other Methods Including Pap

QIAGEN donates one million tests to expand access to HPV screening in the world's poorest countries VENLO, Netherlands, April 1 /PRNewswire-FirstCall/ -- Results from an eight-year trial involving more than 130,000 women published today in The New England Journal of Medicine (NEJM) demonst...

First Published Study of New HPV Test for Developing Countries Shows High Accuracy in Predicting Cervical Disease

QIAGEN's careHPV test provides 'substantially more accurate' front-line screening VENLO, Netherlands, Sept. 21 /PRNewswire-FirstCall/ -- A new HPV test developed by QIAGEN specifically for use in regions of the world with scarce resources is "substantially" more a...

Ending Cervical Cancer Featured at Summit; QIAGEN CEO Issues a Call to Global Women Leaders

HANOI, Vietnam, June 6 /PRNewswire-FirstCall/ -- QIAGEN was featured this week for its efforts to eliminate cervical cancer at the 14th annual Global Summit of Women in Hanoi, Vietnam. CEO Peer Schatz came to this prominent international platform to issue a call to other leaders in business, N...

Study Finds QIAGEN's HPV Test Offers Greater Long-term Protection From Cervical Disease Than the Pap

HILDEN, Germany, May 21 /PRNewswire-FirstCall/ -- - Research Supports Replacement of Pap With HPV Test as Front-line Screen Long-term data from a study published in the International Journal of Cancer show that women screened only with a human papillomavirus (HPV) DNA test are half as like...

Nventa Announces Additional Positive Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial

All Patients in Cohort 3 Demonstrated Improvement in T-Cell Responses Further Supporting the Therapeutic Potential of HspE7 SAN DIEGO, May 12 /PRNewswire-FirstCall/ -- Nventa Biopharmaceuticals Corporation (TSX: NVN) today announced positive immunological data from the third cohort of...

Globus Medical Completes Enrollment Of SECURE(R)-C Cervical Artificial Disc Clinical Trial

MIAMI, May 8 /PRNewswire/ -- Globus Medical, Inc., the largest privately held spinal implant manufacturer in the world and a recognized leader in motion preservation technology, today announced the completion of enrollment in its SECURE(R)-C Cervical Artificial Disc IDE study. The SECURE(R)-C ...

Nventa Completes Safety Evaluation on Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial

- HspE7 Phase 2 Trial for Cervical Dysplasia to Begin Mid-2008 - SAN DIEGO, April 24 /PRNewswire-FirstCall/ -- Nventa Biopharmaceuticals Corporation (TSX: NVN) today announced the completion of the safety and tolerability assessment of the fourth and final cohort of patients in its Phase 1...

Gen-Probe Begins U.S. Clinical Study of Molecular Test for Human Papillomavirus, Which Causes Cervical Cancer

SAN DIEGO, March 31 /PRNewswire-FirstCall/ -- Gen-Probe Incorporated (Nasdaq: GPRO ) announced today that the Company has begun a pivotal U.S. clinical trial of its investigational APTIMA(R) assay to detect human papillomavirus (HPV), which causes cervical cancer. "Starting this highly comp...

Nventa Announces Positive Interim Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial

3 out of 4 Patients in Cohort 2 Demonstrate T-Cell Responses Indicating Potential HspE7 Therapeutic Benefit SAN DIEGO, March 26 /PRNewswire-FirstCall/ -- Nventa Biopharmaceuticals Corporation (TSX: NVN) today announced interim immunological data from the first two cohorts of i...

Nventa Enrolls and Initiates Dosing of Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial

SAN DIEGO, March 11 /PRNewswire-FirstCall/ -- Nventa Biopharmaceuticals Corporation (TSX: NVN) today announced that the Company has completed enrollment and initiated dosing of the fourth and final cohort of patients in its Phase 1 dose escalation trial. This study examines the safety of its l...

GSK Cervical Cancer Candidate Vaccine CERVARIX (R) Demonstrates Long-Term Protection for More Than Six Years

New study results also demonstrate the longest duration of consistently high antibody levels shown by a cervical cancer vaccine TAMPA, Fla., March 10 /PRNewswire-FirstCall/ -- New data demonstrate that GlaxoSmithKline's (NYSE: GSK ) cervical cancer candidate vaccine, CERVARIX(R) provid...

Nventa Evaluation Complete for First Three Cohorts in HspE7 Phase 1 Cervical Dysplasia Trial

- HspE7 Well Tolerated; Fourth Cohort to be Dosed Shortly - SAN DIEGO, March 3 /PRNewswire-FirstCall/ -- Nventa Biopharmaceuticals Corporation (TSX: NVN) today announced the completion of the safety and tolerability assessment of its third cohort of patients in a Phase 1 clinical trial o...

New Study Shows Listeria Vaccine for Cervical Cancer Found Safe

NORTH BRUNSWICK, N.J., Oct. 16 /PRNewswire-FirstCall/ -- Researchers testing a vaccine based on the live bacteria Listeria, in women with advanced cervical cancer found it to be safe. The Lovaxin C vaccine being developed by Advaxis Inc. (OTC Bulletin Board: ADXS), is intended to treat cervica...

The First Annual Cervical Cancer/HPV Conference Tackles Controversial Vaccine Issues and Encourages Advocacy

National Cervical Cancer Coalition unites women in joining the fight for education and early detection and prevention of the Human Papillomavirus (HPV) and cervical cancer WASHINGTON, Sept. 21 /PRNewswire-USNewswire/ -- More than 80 women and men gathered at the Hyatt R...

Spine Institute of Louisiana Offers Cervical Spine Motion Preservation as an Alternative to Fusion Surgery

KATRINA EVACUEE BENEFITS FROM FIRST EVER TWO-LEVEL TOTAL DISC REPLACEMENT PERFORMED IN LOUISIANA SHREVEPORT, La., Sept. 12 /PRNewswire/ -- The Spine Institute of Louisiana, in conjunction with SpineMark Corporation, is now offering cervical spine motion preservation proc...

Nventa Announces Presentation of Positive HspE7 Data from NCI-Sponsored Clinical Trial in Cervical Dysplasia

- 78 Percent of Patients Showed Complete Response or Reduction of Lesion Size by More than Fifty Percent - SAN DIEGO, CA, March 05, 2007 /PRNewswire-FirstCall/ - Nventa Biopharmaceuticals Corporation today announced the presentation of positive results from a clinical trial examining the safety an...

Cervarix, GSK Cervical Cancer Candidate Vaccine, Demonstrates 100 Percent Protection Against Precancerous Lesions Caused By Cancer-Causing Human Papillomavirus Types 16 & 18 for More Than Five Years

New study results also show evidence of additional protection against infection with other cancer-causing virus types LOS ANGELES, April 17, 2007 /PRNewswire-FirstCall/ -- The GlaxoSmithKline cervical cancer candidate vaccine, CERVARIX(R), demonstrated 100 percent efficacy in preventing precancero...

New England Journal of Medicine Publishes New Data on Gardasil, Merck's Cervical Cancer Vaccine

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)-May 10, 2007--Today, the New England Journal of Medicine is publishing results from two Phase III studies of Merck's cervical cancer vaccine, Gardasil (Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine). In the first study, Gardasi...

Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides Sustained Immune Response in 100 Percent of Women up to 55 Years of Age

New Study Results Show Antibodies Against Cancer-Causing Virus Types 16 & 18 That Are At Least Ten Times Greater Than Natural Infection Levels CHICAGO, June 05, 2007 /PRNewswire/ -- New Phase III data show that at 18 months after the first of a three-dose regimen, 100 percent of women up to ag...

Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types

Results also show significant additional protection against infection with virus types beyond 16 and 18 with the GSK cervical cancer candidate vaccine PHILADELPHIA, June 27, 2007 /PRNewswire-FirstCall/ -- Results from an interim analysis of a Phase III study show that CERVARIX(R), the GlaxoSmithKl...

Vaccine Can Prevent Cervical Cancer and Precancerous Lesions

LONDON, June 28, 2007--A cervical cancer vaccine has shown 90% efficacy for prevention of cervical cancer and precancerous lesions associated with the human papillomavirus (HPV) types targeted by the vaccine, conclude authors of an Article published early Online and in the upcoming issue of The Lan...

Cytokine PharmaSciences Initiates Phase I Study of Oral Anti-Inflammatory Agent, CPSI-2364

...nd manufactures controlled-release drug delivery products and has a strong focus in the area of women's health, including manufacturing the successful cervical ripening product, the Cervidil(R) vaginal insert (Propess(R) in Europe and elsewhere). Cytokine PharmaSciences has three products in clinical developm...

University of Michigan Study Shows SEQUENOM's MassARRAY Technology Identifies HPV Infections Missed by Standard Hybridization Test

...roximately 9,000 American women are diagnosed with cervical cancer each year despite regular cervical screening. The study, titled, Development and Eva... be an important advance in the early detection of cervical cancer." Study Methodology 1...

Great Basin Scientific, Inc. Raises $3.6 Million in Bridge Funding to Prepare for Launch of First Product

... sepsis and meningitis in newborns, and Human Papilloma Virus (HPV), the most common sexually transmitted infection of which certain types can lead to cervical cancer. Great Basin Scientific's technology has several advantages over the traditional Polymerase Chain Reaction (PCR) method that requires th...

Merz Pharmaceuticals Announce Three Studies of NT-201 - (Botulinum neurotoxin type A Free From Complexing Proteins)

... in upper limb post-stroke spasticity, pre-treated cervical dystonia, and treatment-naive cervical dystonia patients represent the second data set pr...pe A free from complexing proteins) in pre-treated cervical dystonia patients, Efficacy and safety of NT-201 (...

Merz Pharmaceuticals Announces Results of Clinical Trials with NT-201(Botulinum neurotoxin type A free from complexing proteins) at Annual Movement Disorders Society Meeting

...clinical trials in patients with blepharospasm and cervical dystonia -- one placebo-controlled spasticity tria...ations of symptomatic management of blepharospasm, cervical dystonia and post-stroke spasticity of the upper l...1 to one other botulinum toxin in the treatment of cervical dystonia," said Pappert. First Study - Ti...

Merz Pharmaceuticals Announces Results of Three Clinical Trials With NT-201 (Botulinum Neurotoxin Type A Free From Complexing Proteins) in Movement Disorder Patients

...o controlled multi-center studies in patients with cervical dystonia and blepharospasm, and pooled European ef...ations of symptomatic management of blepharospasm, cervical dystonia and post-stroke spasticity of the upper l...linum neurotoxin free from complexing proteins) in cervical dystonia, poster p07.081 , Clinical efficacy in...

BioMarin Initiates Phase 1/2 Clinical Trial for GALNS for Morquio A Syndrome

...he lung likely impairs respiratory function and contributes to sinopulmonary infections. Odontoid dysplasia and ligamentous laxity can commonly cause cervical spinal instability and potentially spinal cord compression. Other symptoms may include recurrent infections, hearing loss, corneal clouding, and heart...

Society of Gynecologic Oncologists 40th Annual Meeting on Women's Cancer to Include Sessions on Robotics Surgery

...nt of gynecologic malignancies such as uterine and cervical cancer," explains Dr. M. Patrick Lowe, Director of... the patient. Patients who suffer from uterine and cervical cancer are the most viable candidates for robotic-...aditional surgery for the treatment of uterine and cervical cancers." About the Society of Gynecologic ...

Study Shows No Standardized Approach to Epidural Steroid Injections for Back Pain

...r (low back) region are low risk, injections in the thoracic (mid back) and cervical (neck) region have the risk of injury to the spinal cord and brain. It usu...are giving very high volumes (up to 10 cc) of steroids in areas such as the cervical epidural space. In limited enclosed areas like the cervical region that vo...

Observational Study Finds Changes in Medicare Reimbursement for Erythropoiesis-Stimulating Agents Associated With Increased Need for Blood Transfusion

...reased the risk of tumor progression or recurrence in some clinical studies in patients with breast, non-small cell lung, head and neck, lymphoid, and cervical cancers (see WARNINGS: Table 1). To decrease these risks, as well as the risk of serious cardio- and thrombovascular events, use the lowest ...

Hologic Releases the Results of the Cervista(TM) HPV Clinical Trials

...e test is as a general screen, in combination with cervical cytology (pap test), to help guide patient managem...9.1%. Patients with CIN2 are at risk of developing cervical cancer, however this risk is not as high as it is ...which are responsible for approximately 70% of all cervical cancers. The Cervista(R) 16/18 test is also pendin...

Data From Investigational Use of PROCRIT(R) (Epoetin alfa) Presented at American Society of Nephrology Annual Meeting

... risk of tumor progression or recurrence in some clinical studies in patients with breast, non-small cell lung, head and neck, lymphoid, and cervical cancers (see WARNINGS: Table 1). -- To decrease these risks, as well as the risk of serious cardio- and thrombovascular events, use the ...

Healthy Bones Program Reduces Hip Fractures by 37 Percent, Kaiser Permanente Study Finds

...stain a fragility fracture in their lifetime. The mortality rate due to osteoporosis-related fractures is greater than the rates for breast cancer and cervical cancer combined," said study lead author Richard M. Dell, MD, an orthopedic surgeon at the Kaiser Permanente Bellflower Medical Center. "Yet it's a mi...

CEL-SCI Announces Expansion of Exclusive Licensing Agreement for Cancer Drug Multikine

...ines, Australia and New Zealand. The licensing agreement initially focuses on the areas of head and neck cancer, nasopharyngeal cancer and potentially cervical cancer. As part of this new agreement, Orient Europharma will invest $500,000 in CEL-SCI and fund a portion of the Company's global Phase III clinic...

Susan G. Komen for the Cure(R) Makes Unprecedented Research and Local Program Grants

...s research grants, this represents an amazing step in our promise to end breast cancer forever." Dr. Burack's project will provide Breast Cancer and cervical Control Program (BCCCP) services to underinsured and at-risk women in Wayne County. Dr. Hammad's ACCESS project will continue to provide an extensive ...
Other Tags
(Date:9/18/2014)... BUFFALO, N.Y. A sleep-promoting circuit located deep in ... deep sleep. Discovered by researchers at Harvard School of ... and Biomedical Sciences, this is only the second "sleep ... to be both necessary and sufficient to produce deep ... Neuroscience , the study demonstrates that fully half of ...
(Date:9/18/2014)... Worcester, Mass. A novel robotic system that can ... currently being tested as part of a biomedical research ... with the aim of determining if the robot, in ... biopsies faster, more accurate, less costly, and less discomforting ... potential to deliver prostate cancer therapies with greater precision. ...
(Date:9/18/2014)... No matter how many times it,s demonstrated, it,s ... creatures. , But by using a signaling ... alter their behavior to suit their population. In ... are present, and act accordingly. , Once the ... may change from innocuous to pathogenic, or from ...
Breaking Biology News(10 mins):No sedative necessary: Scientists discover new 'sleep node' in the brain 2Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 2Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 3Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 4Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 5Researchers study vital 'on/off switches' that control when bacteria turn deadly 2Researchers study vital 'on/off switches' that control when bacteria turn deadly 3
(Date:9/20/2014)... -- As flu season approaches, the best way to ... flu shot and a checkup, according to an infectious ... vaccinate people against the flu, and also address other ... may provide flu shots for their customers, but they ... medical director of infection prevention and control for the ...
(Date:9/20/2014)... 2014 As concerns surrounding the ... in gynecological surgeries continue to grow, Bernstein Liebhard ... plans to end coverage for uterine morcellation. According ... month, Harrisburg, Pennsylvania-based Capital BlueCross will end coverage ... insurer said its decision was prompted by concerns ...
(Date:9/20/2014)... Traditionally dentists have advised their patients against drinking ... is re-visiting that advice and changing his stance after ... wine have on oral health. “There’s good news and great ... be beneficial in protecting against gum disease, and red wine ... coffee was from the September 2014 issue of Boston ...
(Date:9/20/2014)... 20, 2014 Earlier this week, Home Depot ... have had their credit card information pilfered by hackers, surpassing ... slew of headline articles like this one published ... eye opening numbers. , “Most people tend to focus ... it’s a way to score a game,” says Joe Caruso, ...
(Date:9/20/2014)... 2014 The Arizona Advanced Manufacturing ... celebrating National Manufacturing Day by opening its doors to ... and additive manufacturing labs will be offered between 10 ... MCC’s Southern and Dobson campus (1833 W. Southern Ave, ... D. , The AzAMI at MCC was established in ...
Breaking Medicine News(10 mins):Health News:Get a Flu Shot During Checkup, Doctor Says 2Health News:As Power Morcellator Concerns Grow, Bernstein Liebhard LLP Notes Another Insurer’s Decision to Drop Coverage for Uterine Morcellation 2Health News:As Power Morcellator Concerns Grow, Bernstein Liebhard LLP Notes Another Insurer’s Decision to Drop Coverage for Uterine Morcellation 3Health News:South Charlotte Dentist, Dr. James Wells, is Changing His Advice on Coffee and Wine Drinking 2Health News:South Charlotte Dentist, Dr. James Wells, is Changing His Advice on Coffee and Wine Drinking 3Health News:Don’t Let Data Breach Fatigue Cause Dangerous Cyber Security Complacency 2Health News:Don’t Let Data Breach Fatigue Cause Dangerous Cyber Security Complacency 3Health News:Don’t Let Data Breach Fatigue Cause Dangerous Cyber Security Complacency 4Health News:Don’t Let Data Breach Fatigue Cause Dangerous Cyber Security Complacency 5Health News:National Manufacturing Day Open House at Mesa Community College Oct. 3 2
Other Contents